bluuebunny/crossref_metadata_2025_split huggingface dataset:
Judicial outcome and follow up of abused child protection acts in a pediatric emergency department: 12-year experience in a third level pediatric hospital
Authors: Poropat Federico , Canuto Arianna , Caddeo Giulia , Predonzani Erica , Novello Laura , Zorzetto Alessandra , Germani Claudio , Barbi Egidio 
Published: May 2020

Abstract
Background
Italian laws allow the protection of a child who is suspected to be a victim of abuse through a procedure that can be put in motion by the attending physician in any Emergency Department (article nr. 403 Civil Code) with a temporarily suspension of parental authority.
This study aims at evaluating both the appropriateness of the activation of the protection procedure by ED doctors in cases of suspected child abuse in terms of judicial confirmation and how it impacts children in the long-term.

Methods
We selected cases in which the procedure was activated due to suspected child abuse. The children were admitted to the ED of a tertiary children hospital from 2006 to 2018. We then reviewed the medical charts and collected data from the social services through a questionnaire concerning the long-term outcomes .

Results
Twenty-eight patients were included (75% females, mean age 13.8 years). In 90% of cases the activation of the procedure in the ED was followed by a Court confirmation. Evaluation of long term outcome was possible in 22 cases. Among them, a positive social outcome was achieved in 15 cases (68.2%). The remaining abandoned the program or had critical reintegration in the family. Eighteen percent of patients developed major issues such as aberrant behaviours, substance abuse or psychiatric disorders.

Conclusions
This report identifies a good ability of ED doctors in the activation of an emergency procedure to protect the child. Overall, the social outcome was good for nearly 70% of the patients, highlighting the importance of activation of social support programs for child abuse.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Authors: Martínez-Sáez Olga , Chic Nuria , Pascual Tomás , Adamo Barbara , Vidal Maria , González-Farré Blanca , Sanfeliu Esther , Schettini Francesco , Conte Benedetta , Brasó-Maristany Fara , Rodríguez Adela , Martínez Débora , Galván Patricia , Rodríguez Ana Belén , Martinez Antonio , Muñoz Montserrat , Prat Aleix 
Published: May 2020

AbstractPurposeThe therascreenPIK3CAmutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advancedPIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects mostPIK3CAmutations in BC. This information is critical as patients and clinicians are using this and other genomic assays to indicate alpelisib.MethodsData from 6338 patients with BC was explored across 10 publicly available studies. The primary objective was to evaluate the proportion and distribution ofPIK3CAmutations in BC. Secondary objectives were (1) to evaluate in silico the spectrum ofPIK3CAmutations in BC that would be captured by the therascreen panel; (2) to evaluate the proportion and distribution ofPIK3CAmutations in hormone receptor-positive/HER2-negative (HR+/HER2−), HER2+, and triple-negative BC (TNBC); and (3) to explore the identification ofPIK3CAmutations in a cohort of 48 HR+/HER2− advanced BC patients by the Guardant B360 circulating tumor DNA (ctDNA) assay.ResultsPatients withPIK3CAmut tumors represented 35.7% (2261/6338). FivePIK3CAmutations comprised 73% of allPIK3CAmutations: H1047R (35%), E545K (17%), E542K (11%), N345K (6%), and H1047L (4%). Therascreen gene list would capture 72% of allPIK3CAmutations and 80% of patients with a knownPIK3CAmut BC. Among patients with doublePIK3CAmut tumors (12% of allPIK3CAmut), the therascreen panel would capture 78% as harboring 1 singlePIK3CAmutation, 17% asPIK3CAmut undetected, and 5% asPIK3CAdouble-mut.PIK3CAmutation rates were lower in TNBC (16%) compared to HR+/HER2 (42%) and HER2+ (31%) BC; however, the distribution of the 4 mainPIK3CAmutations across subtypes was similar. Finally, 28% ofPIK3CAmutations identified in ctDNA in 48 patients with advanced HR+/HER2− BC were not part of the therascreen panel.ConclusionPIK3CAmutations in BC are heterogenous and ~ 20% of patients with a knownPIK3CAmutation, and 95% with a known doublePIK3CAmut tumor, would not be captured by the therascreen panel. Finally, the clinical utility ofPIK3CAmutations not present in the therascreen companion diagnostic assay or identified by other sequencing-based assays needs further investigation.
Relocating a pediatric hospital: Does antimicrobial resistance change?
Authors: Schönfeld Annika , Ascherl Rudolf , Petzold-Quinque Stefanie , Lippmann Norman , Rodloff Arne C. , Kiess Wieland 
Published: May 2020

Abstract
Objective
Analyze the changes in antimicrobial drug resistance patterns due to hospital relocation. To this end, we conducted a retrospective analysis of microbiological results, especially minimum inhibitory concentrations (MIC) of all isolates from blood, urine and bronchial secretions, in our pediatric university hospital before and after moving to a new building.

Results
While the number of tests done did not change, the fraction of those positive increased, more MICs were determined and certain microbes (A. baumannii, E. faecalis, Klebsiella spp. and P. mirabilis) were detected more frequently. Most changes in MICs occurred in E. faecium (increases in 8 antimicrobials, decreases only in linezolid and gentamicin). For imipenem and aminopenicillins the MICs commonly rose after relocation, the opposite is true for gentamicin and trimethoprim/sulfamethoxazole. The other factors that alter by moving a hospital such as changes in medical personnel or case severity cannot be corrected for, but using MICs we are able to provide insights into changes down to the individual antimicrobial drug and even small changes usually undetectable to the common categorical reporting of resistance.
Microarray analysis of formalin-fixed, paraffin-embedded follicular thyroid carcinoma samples from patients who developed postoperative distant metastasis
Authors: Jikuzono Tomoo , Ishikawa Tomoko , Hirokawa Mitsuyoshi , Sugitani Iwao , Ishibashi Osamu 
Published: May 2020

Abstract
Objective
Although follicular thyroid carcinoma (FTC) generally has a good prognosis, it occasionally metastasises, leading to poor prognosis. Unfortunately, minimally invasive FTC (mi-FTC) and encapsulated angioinvasive FTC (ea-FTC) cannot be distinguished cytopathologically from thyroid follicular adenoma (FTA), a benign tumour with a good prognosis. Therefore, a molecular diagnosis to distinguish mi- or ea-FTC from FTA is needed for clinical treatment. Several transcriptomics/proteomics studies have searched for FTC biomarkers. However, the results of these studies were not consistent, which could be partly explained by inaccurate diagnosis of the specimens analysed.

Data description
We conducted a microarray-based genome-wide transcriptome analysis using formalin-fixed paraffin-embedded mi- or ea-FTC specimens from patients who developed distant metastasis up to 10 years postoperatively, which ensured the accuracy of diagnosis.
Relevance of biomarkers across different neurodegenerative diseases
Authors: Ehrenberg Alexander J. , Khatun Ayesha , Coomans Emma , Betts Matthew J. , Capraro Federica , Thijssen Elisabeth H. , Senkevich Konstantin , Bharucha Tehmina , Jafarpour Mehrsa , Young Peter N. E. , Jagust William , Carter Stephen F. , Lashley Tammaryn , Grinberg Lea T. , Pereira Joana B. , Mattsson-Carlgren Niklas , Ashton Nicholas J. , Hanrieder Jörg , Zetterberg Henrik , Schöll Michael , Paterson Ross W. 
Published: May 2020

AbstractBackgroundThe panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is growing and has the potential to close important gaps in research and the clinic. With this growth and increasing use, appropriate implementation and interpretation are paramount. Various biomarkers feature nuanced differences in strengths, limitations, and biases that must be considered when investigating disease etiology and clinical utility. For example, neuropathological investigations of Alzheimer’s disease pathogenesis can fall in disagreement with conclusions reached by biomarker-based investigations. Considering the varied strengths, limitations, and biases of different research methodologies and approaches may help harmonize disciplines within the neurodegenerative disease field.Purpose of reviewAlong with separate review articles covering fluid and imaging biomarkers in this issue ofAlzheimer’s Research and Therapy, we present the result of a discussion from the 2019 Biomarkers in Neurodegenerative Diseases course at the University College London. Here, we discuss themes of biomarker use in neurodegenerative disease research, commenting on appropriate use, interpretation, and considerations for implementation across different neurodegenerative diseases. We also draw attention to areas where biomarker use can be combined with other disciplines to understand issues of pathophysiology and etiology underlying dementia. Lastly, we highlight novel modalities that have been proposed in the landscape of neurodegenerative disease research and care.
Increasing allergy: are antibiotics the elephant in the room?
Authors: Herman Rod A. 
Published: May 2020

AbstractAntibiotics cause dramatic changes to the human microbiome. The composition of the microbiome has been associated with changes in the immune system and these changes are beginning to be linked to immune diseases. Thus, antibiotics have been implicated as a significant contributor to the continual rise of allergies and autoimmune disease in developed countries. This recognition will hopefully result in the development of post-antibiotic therapies that restore a healthy microbiome and reduce immune system disorders.
Evaluation of local and systemic immune responses in pigs experimentally challenged with porcine reproductive and respiratory syndrome virus
Authors: Nazki Salik , Khatun Amina , Jeong Chang-Gi , Mattoo Sameer ul Salam , Gu Suna , Lee Sim-In , Kim Seung-Chai , Park Ji-Hyo , Yang Myoun-Sik , Kim Bumseok , Park Choi-Kyu , Lee Sang-Myeong , Kim Won-Il 
Published: May 2020

AbstractThe host-associated defence system responsible for the clearance of porcine reproductive and respiratory syndrome virus (PRRSV) from infected pigs is currently poorly understood. To better understand the dynamics of host–pathogen interactions, seventy-five of 100 pigs infected with PRRSV-JA142 and 25 control pigs were euthanized at 3, 10, 21, 28 and 35 days post-challenge (dpc). Blood, lung, bronchoalveolar lavage (BAL) and bronchial lymph node (BLN) samples were collected to evaluate the cellular immune responses. The humoral responses were evaluated by measuring the levels of anti-PRRSV IgG and serum virus-neutralizing (SVN) antibodies. Consequently, the highest viral loads in the sera and lungs of the infected pigs were detected between 3 and 10 dpc, and these resulted in moderate to mild interstitial pneumonia, which resolved accompanied by the clearance of most of the virus by 28 dpc. At peak viremia, the frequencies of alveolar macrophages in infected pigs were significantly decreased, whereas the monocyte-derived DC/macrophage and conventional DC frequencies were increased, and these effects coincided with the early induction of local T-cell responses and the presence of proinflammatory cytokines/chemokines in the lungs, BAL, and BLN as early as 10 dpc. Conversely, the systemic T-cell responses measured in the peripheral blood mononuclear cells were delayed and significantly induced only after the peak viremic stage between 3 and 10 dpc. Taken together, our results suggest that activation of immune responses in the lung could be the key elements for restraining PRRSV through the early induction of T-cell responses at the sites of virus replication.
Interleukin 4 inducible 1 gene (IL4I1) is induced in chicken phagocytes by Salmonella Enteritidis infection
Authors: Elsheimer-Matulova Marta , Polansky Ondrej , Seidlerova Zuzana , Varmuzova Karolina , Stepanova Hana , Fedr Radek , Rychlik Ivan 
Published: May 2020

AbstractIn attempt to identify genes that are induced in chickens by Salmonella Enteritidis we identified a new highly inducible gene, interleukin 4 induced 1 gene (IL4I1). IL4I1 reached its peak expression (458× induction) in the cecum of newly hatched chickens 4 days post-infection and remained upregulated for an additional 10 days. IL4I1 was expressed and induced in macrophages and granulocytes, both at the mRNA and protein level. IL4I1 was expressed and induced also in CD4 and γδ T-lymphocytes though at a 50-fold lower level than in phagocytes. Expression of IL4I1 was not detected in CD8 T lymphocytes or B lymphocytes. Mutation of IL4I1 in chicken HD11 macrophages did not affect their bactericidal capacity against S. Enteritidis but negatively affected their oxidative burst after PMA stimulation. We therefore propose that IL4I1 is not directly involved in bactericidal activity of phagocytes and, instead, it is likely involved in the control of inflammatory response and signaling to T and B lymphocytes.
Beneficial effect modification on survival outcome of sepsis between ART-123 and polymyxin B‑immobilised haemoperfusion: a nationwide Japanese registry study
Authors: Mochizuki Katsunori , Mori Kotaro , Kamijo Hiroshi , Ichikawa Michitaro , Nitta Kenichi , Imamura Hiroshi 
Published: May 2020

AbstractBackgroundAlthough recently published randomised controlled trials did not confirm significant positive effect of ART-123 or polymyxin B‑immobilised haemoperfusion (PMX-HP) on survival outcome, previous studies using a dataset of 3195 patients with sepsis registered at 42 intensive care units throughout Japan revealed significantly reduced mortality following these treatments. A study has suggested the efficacy of combination therapy with ART-123 and PMX-HP; however, it did not evaluate the effect modification between them. We hypothesised that coadministration of ART-123 and PMX-HP has a significant positive effect modification on survival outcome. The purpose of this study was to evaluate the effect modification between ART-123 and PMX-HP treatment on the survival outcome of sepsis using post hoc analysis of the dataset of the Japan Septic Disseminated Intravascular Coagulation registry.ResultsOf the 3195 patients recorded in the registry, 2350 were analysed. The product term between ART-123 and PMX-HP was analysed by the Cox regression model to evaluate significance. The primary outcome of this study was hospital mortality. Although the administration of ART-123 was independently positively associated with survival outcome (adjusted hazard ratio [HR]: 0.834, 95% confidence interval [CI] 0.695–0.999;P = 0.049) in the model prior to the introduction of the product term, a significant effect modification on survival outcome was observed between the administration of ART-123 and PMX-HP treatment (adjusted HR: 0.667, 95% CI 0.462–0.961;P = 0.030).ConclusionsThe main effect of the administration of ART-123 may be beneficial for survival outcome in patients with sepsis. In addition, a significant beneficial effect modification on survival outcome was observed between the administration of ART-123 and PMX-HP treatment.
The role of passive immunization in the age of SARS-CoV-2: an update
Authors: Fischer Johannes C. , Zänker Kurt , van Griensven Martijn , Schneider Marion , Kindgen-Milles Detlef , Knoefel Wolfram Trudo , Lichtenberg Artur , Tamaskovics Balint , Djiepmo-Njanang Freddy Joel , Budach Wilfried , Corradini Stefanie , Ganswindt Ute , Häussinger Dieter , Feldt Torsten , Schelzig Hubert , Bojar Hans , Peiper Matthias , Bölke Edwin , Haussmann Jan , Matuschek Christiane 
Published: May 2020

AbstractThe rapid spread of the corona virus pandemic is an existential problem for many people in numerous countries. So far, there is no effective vaccine protection or proven therapy available against the SARS-CoV-2 virus. In this review, we describe the role of passive immunization in times of the corona virus. Passive immunization could be a bridging technology to improve the immune defense of critically ill patients until better approaches with effective medications are available.
Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
Authors:   the MoMar study group, Weber Daniel G. , Casjens Swaantje , Brik Alexander , Raiko Irina , Lehnert Martin , Taeger Dirk , Gleichenhagen Jan , Kollmeier Jens , Bauer Torsten T. , Brüning Thomas , Johnen Georg 
Published: May 2020

Abstract
Background
For the detection of malignant mesothelioma additional markers are needed besides the established panel consisting of calretinin and mesothelin. The aim of this study was the identification and verification of long non-coding RNAs (lncRNAs) as complementing circulating markers.

Methods
Candidate lncRNAs were identified in silico using previously published RNA expression profiles and verified using quantitative PCR (qPCR) in mesothelioma cell lines as well as human plasma samples from mesothelioma patients and asbestos-exposed controls.

Results
GAS5 (growth arrest-specific transcript 5) as a single marker is marked by a low sensitivity of 14%, but the combination of GAS5 with calretinin and mesothelin increased the panel’s sensitivity from 64 to 73% at a predefined specificity of 97%. Circulating GAS5 is not affected by pleurectomy before blood collection, age, or smoking status.

Conclusions
GAS5 is verified as an appropriate circulating marker for the supplement of calretinin and mesothelin to detect malignant mesothelioma. Although the sensitivity of GAS5 is too low for the use as a single marker, the addition of GAS5 as a third marker improves the performance of the established marker panel. The benefit of GAS5 for the detection of malignant mesothelioma at early stages needs to be validated in a prospective study.
Trends and projections of kidney cancer incidence at the global and national levels, 1990–2030: a Bayesian age-period-cohort modeling study
Authors: Du Zhebin , Chen Wei , Xia Qier , Shi Oumin , Chen Qi 
Published: May 2020

AbstractBackgroundIdentifying the temporal trends of kidney cancer (KC) incidence in both the past and the future at the global and national levels is critical for KC prevention.MethodsWe retrieved annual KC case data between 1990 and 2017 from the Global Burden of Disease (GBD) online database. The average annual percentage change (AAPC) was used to quantify the temporal trends of KC age-standardized incidence rates (ASRs) from 1990 to 2017. Bayesian age-period-cohort models were used to predict KC incidence through 2030.ResultsWorldwide, the number of newly diagnosed KC cases increased from 207.3 thousand in 1990 to 393.0 thousand in 2017. The KC ASR increased from 4.72 per 100,000 to 4.94 per 100,000 during the same period. Between 2018 and 2030, the number of KC cases is projected to increase further to 475.4 thousand (95% highest density interval [HDI] 423.9, 526.9). The KC ASR is predicted to decrease slightly to 4.46 per 100,000 (95% HDI 4.06, 4.86). A total of 90, 2, and 80 countries or territories are projected to experience increases, remain stable, and experience decreases in KC ASR between 2018 and 2030, respectively. In most developed countries, the KC incidence is forecasted to decrease irrespective of past trends. In most developing countries, the KC incidence is predicted to increase persistently through 2030.ConclusionsKC incidence is predicted to decrease in the next decade, and this predicted decrease is mainly driven by the decreases in developed countries. More attention should be placed on developing countries.
Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets
Authors:   on behalf of the Advancing Treatment for Pediatric Craniopharyngioma Consortium, Prince Eric , Whelan Ros , Donson Andrew , Staulcup Susan , Hengartner Astrid , Vijmasi Trinka , Agwu Chibueze , Lillehei Kevin O. , Foreman Nicholas K. , Johnston James M. , Massimi Luca , Anderson Richard C. E. , Souweidane Mark M. , Naftel Robert P. , Limbrick David D. , Grant Gerald , Niazi Toba N. , Dudley Roy , Kilburn Lindsay , Jackson Eric M. , Jallo George I. , Ginn Kevin , Smith Amy , Chern Joshua J. , Lee Amy , Drapeau Annie , Krieger Mark D. , Handler Michael H. , Hankinson Todd C. 
Published: May 2020

AbstractAdamantinomatous craniopharyngioma (ACP) is a biologically benign but clinically aggressive lesion that has a significant impact on quality of life. The incidence of the disease has a bimodal distribution, with peaks occurring in children and older adults. Our group previously published the results of a transcriptome analysis of pediatric ACPs that identified several genes that were consistently overexpressed relative to other pediatric brain tumors and normal tissue. We now present the results of a transcriptome analysis comparing pediatric to adult ACP to identify biological differences between these groups that may provide novel therapeutic insights or support the assertion that potential therapies identified through the study of pediatric ACP may also have a role in adult ACP. Using our compiled transcriptome dataset of 27 pediatric and 9 adult ACPs, obtained through the Advancing Treatment for Pediatric Craniopharyngioma Consortium, we interrogated potential age-related transcriptional differences using several rigorous mathematical analyses. These included: canonical differential expression analysis; divisive, agglomerative, and probabilistic based hierarchical clustering; information theory based characterizations; and the deep learning approach, HD Spot. Our work indicates that there is no therapeutically relevant difference in ACP gene expression based on age. As such, potential therapeutic targets identified in pediatric ACP are also likely to have relvance for adult patients.
Together we unite: the role of the Commonwealth in achieving universal health coverage through pharmaceutical care amidst the COVID-19 pandemic
Authors: Chan Amy Hai Yan , Rutter Victoria , Ashiru-Oredope Diane , Tuck Chloe , Babar Zaheer-Ud-Din 
Published: May 2020

AbstractThe world currently faces unprecedented health challenges as COVID-19 poses a huge threat to health systems, economies and societies as we know it. The events of the current COVID-19 pandemic have further emphasised existing issues within our health systems. There is no better time than now to come together in global solidarity to tackle these evolving threats of COVID-19 pandemic. The Commonwealth is an ideally placed network to tackle these global health challenges, with its wide-reaching networks of governmental, non-governmental and civil society organisations across all continents. Although the biennial Commonwealth Heads of Government Meeting (CHOGM) originally scheduled to take place in Kigali in Rwanda 22–27 June 2020 has been postponed in view of COVID-19, Commonwealth country discussions are continuing, centred on the CHOGM key theme of ‘Delivering a Common Future: Connecting, Innovating, Transforming’, and five subthemes of Information and Communications Technology (ICT) and Innovation; Trade; Environment; Governance and the Rule of Law; and Youth. The planned CHOGM and Commonwealth itself provides all members a timely platform to consider innovative ways to connect, innovate and transform healthcare to meet the needs of their populations. This commentary considers these five CHOGM subthemes and how member nations can be supported to achieve universal health coverage through optimising medicines use and outcomes, in the midst of a global pandemic in line with the global health agenda.